Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
about
Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-AnalysisPirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse eventsCXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways.Rho/Rock cross-talks with transforming growth factor-β/Smad pathway participates in lung fibroblast-myofibroblast differentiation.Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study.Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-β1-induced ERK1/2 signaling pathwayInduced Pluripotent Stem Cells Inhibit Bleomycin-Induced Pulmonary Fibrosis in Mice through Suppressing TGF-β1/Smad-Mediated Epithelial to Mesenchymal Transition.Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.Promising new treatment targets in patients with fibrosing lung disorders.Amelioration of bleomycin-induced pulmonary fibrosis by chlorogenic acid through endoplasmic reticulum stress inhibition.Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling.Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice.Pirfenidone for the treatment of idiopathic pulmonary fibrosis.The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis.
P2860
Q26797272-E5A4C57F-4B19-476A-971E-765E7D57FA2CQ26824810-F5BFC620-763F-435E-BAAC-7013279A2E4EQ34046726-3002294A-B715-4FA8-9F1D-D7CEF9699873Q34265555-17469123-CC01-4B20-9B78-F62878A240A3Q35801391-912C7C78-392D-457A-AFD6-44F6B9FD04FDQ35885884-7A6D0137-7396-4B2C-9DBA-ACCE08148064Q36141637-2620F12F-4013-458F-A697-77FD0AB81CCEQ37413716-22B0BFBD-3671-4186-A317-72E4E2D7A808Q37421028-7B732E42-7E78-471A-AE93-9C6B193F4B6AQ38269057-BAD953B6-CD56-4215-9C7E-8F62C2E84025Q38698129-6C0AB646-6FE2-4B5C-B037-54AD4B40DEC5Q41812311-ABCA644A-4699-4A34-9716-01685F26F222Q46675316-44401AB8-D535-4593-97A1-325CD68320EBQ48068644-00875D6B-40A4-4675-93E3-5CE84772BFE9Q50069018-DABBD6C7-8D6E-4F8E-AE37-5C81B2BE83C0
P2860
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@ast
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@en
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@nl
type
label
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@ast
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@en
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@nl
prefLabel
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@ast
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@en
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@nl
P2093
P921
P3181
P1476
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
@en
P2093
G. A. Margaritopoulos
K. M. Antoniou
N. M. Siafakas
P304
P3181
P356
10.1183/09059180.00002113
P407
P577
2013-09-01T00:00:00Z